aTyr Pharma, Inc. (ATYR) Announces Top Line Results for the Phase III EFZO-FIT Study of

Core Points - aTyr Pharma conducted a conference call to discuss the top line results of the Phase III EFZO-FIT study of efzofitimod in pulmonary sarcoidosis [1][2] Group 1 - The conference call was led by Ashlee Dunston, the Senior Director of Investor Relations and Public Affairs at aTyr [1] - The focus of the call was on the Phase III EFZO-FIT study results for efzofitimod, a treatment for pulmonary sarcoidosis [2]